P. Kgagudi

Development of LIBRA-seq for the Guinea Pig Model System as a Tool for the Evaluation of Antibody Responses to Multivalent HIV-1 Vaccines

This paper evaluates multivalent HIV-1 Env immunization strategies in guinea pigs and adapts LIBRA-seq for antibody discovery, finding optimal cocktail sizes and identifying public clonotypes.

Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms

This study investigates how different isotypes of the same HIV-neutralizing antibody achieve enhanced neutralization potency through distinct mechanisms involving hinge and CH1 regions.

Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages

This study evaluates the neutralizing antibody response to NVX-CoV2373 against Omicron sub-lineages after two or three doses, showing improved neutralization with a third dose.

Fc effector activity and neutralization against SARS-CoV-2 BA.4 is compromised in convalescent sera, regardless of the infecting variant

This study shows that convalescent sera and post-vaccination breakthrough infections have reduced neutralization and ADCC activity against SARS-CoV-2 BA.4, despite prior infection with different variants.

Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies

This study compares three HIV MPER-targeting antibodies, showing that CAP206-CH12's dependence on a variable residue limits its neutralization breadth, unlike the conserved residue reliance of 4E10 and VRC42.01.

Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant.

The study assesses neutralizing antibody activity against 501Y.V2 variant post-Ad26.COV2.S vaccination, finding reduced neutralization but potential protection via other immune mechanisms.

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies

This study examines antibody responses to the SARS-CoV-2 501Y.V2 variant in patients hospitalized in early 2021, finding robust cross-reactivity against earlier variants and the 501Y.V3 variant.

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

This study shows that SARS-CoV-2 501Y.V2 pseudovirus escapes neutralization by South African convalescent plasma but not binding, suggesting potential for reinfection and reduced vaccine efficacy.